Bone Morphogenetic Protein (BMP) Market to Reach $772.2 Million by 2035

Bone Morphogenetic Protein (BMP) market is poised for steady growth, with valuations expected to rise from $452.6 million in 2025 to $772.2 million by 2035, reflecting a CAGR of 5.6%. This trajectory is fueled by the global rise in orthopedic disorders and a corresponding increase in surgical interventions. Clinical evidence from PubMed Central confirms that BMPs offer superior bone repair and spinal fusion outcomes compared to traditional grafts, effectively reshaping regenerative medicine. By significantly reducing recovery times and surgical complications, these biologics have become essential in complex healing procedures. Consequently, hospitals maintain their position as the primary end-users, driven by high procedural volumes and the infrastructure to support advanced bone-healing technologies

Browse the full report description of “Bone Morphogenetic Protein (BMP) Market Size, Share & Trends Analysis Report by Product Type (Recombinant Human BMP-2, Recombinant Human BMP-7, Other BMP Variants), by Application (Spinal Fusion Surgeries, Dental Implants, Trauma & Fracture Healing), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/bone-morphogenetic-protein-bmp-market 

The Future of Regenerative Medicine: Top Players Drive Explosive Growth in BMPs

Leading pharma and medtech players, including Medtronic, Johnson & Johnson, and Stryker, are driving innovation in bone regeneration through next-generation BMP therapies, advanced carrier systems, and targeted applications in spinal fusion and dental implants. Strategic expansions, collaborations, and clinical advancements are accelerating adoption, improving patient outcomes, and positioning BMPs at the forefront of regenerative medicine growth.

• Xtant Medical Holdings announced the launch of Trivium, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. 

• In February 2026, Medtronic received FDA Premarket Approval for its INFUSE Bone Graft for use in one- and two-level Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. This milestone establishes INFUSE as the only PMA-approved growth factor bone graft uniquely indicated across ALIF, OLIF, and TLIF surgeries. The approval provides surgeons with a highly validated biologic solution to improve fusion outcomes for patients suffering from degenerative lumbar spine condition

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Product Type
• By Application
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet, Globus Medical, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Bone Morphogenetic Protein (BMP) Market Report Segment

By Product Type

• Recombinant Human BMP-2
• Recombinant Human BMP-7
• Other BMP Variants

By Application

• Spinal Fusion
• Trauma & Fracture
• Dental Implants
• Tissue Engineering & Regenerative Medicine

Global Bone Morphogenetic Protein (BMP) Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bone-morphogenetic-protein-bmp-market